Aurora Kinase B Market Report 2025

This aurora kinase b market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The aurora kinase b market size has grown rapidly in recent years. It will grow from $1.14 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing demand for targeted cancer therapies, a rise in the prevalence of cancer globally, increasing investments in precision medicine, growth in the number of clinical trials, and growth in government funding for cancer research.

The aurora kinase b market size is expected to see rapid growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to rising investments in innovative cancer treatment, rising incidence of drug-resistant cancers, growing research and development, rising demand for combination therapies, and rising prevalence of solid tumors. Major trends in the forecast period include technological advancements, precision medicine, novel therapies, data analytics, and novel therapies.

The growing incidence of cancer is anticipated to drive the expansion of the aurora kinase B market in the future. Cancer is a collection of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade nearby tissues and metastasize to other body parts. The rise in cancer cases is attributed to factors such as an aging population, lifestyle changes, environmental exposures, and advancements in detection and diagnosis. Aurora kinase B is a crucial enzyme involved in mitosis, and its overexpression is associated with chromosomal instability and cancer progression. It is often targeted in cancer treatments due to its role in tumor cell division. For example, the World Health Organization reported in February 2024 that approximately 20 million new cancer cases were diagnosed in 2022, with 9.7 million deaths. By 2050, new cancer cases are projected to surpass 35 million, a 77% increase from 2022. This rising incidence of cancer is driving the growth of the aurora kinase B market.

Key players in the aurora kinase B market are focusing on developing novel products such as aurora kinase inhibitors, which specifically target and disrupt essential processes in cell division. Aurora kinase inhibitors are drugs designed to block the activity of Aurora kinases, crucial for cell division, thereby hindering the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) approved its EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is being developed for the treatment of acute myeloid leukemia (AML) and targets both FLT3 and Aurora kinase. This dual inhibition strategy is aimed at AML patients who have developed resistance to FLT3 inhibitors, with research showing that it can overcome resistance to selective FLT3 inhibition in both laboratory and clinical settings.

In June 2024, Gedeon Richter Plc., a pharmaceutical company based in Hungary, acquired BCI Pharma for $13.3 million. This acquisition boosts Richter's capabilities in developing targeted treatments for conditions such as cancer and endometriosis. BCI Pharma, based in Belgium, specializes in manufacturing aurora kinase B inhibitors.

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc.

North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aurora kinase b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aurora kinase B is a protein enzyme crucial for cell division, especially during mitosis. It helps regulate chromosome alignment, segregation, and the accurate distribution of genetic material to daughter cells. Aurora kinase B is vital for genomic stability, and its improper regulation is often linked to various cancers.

The main types of aurora kinase B inhibitors include AZD-2811, CS-2164, danusertib, ilorasertib, NMI-900, and others. AZD-2811 is a nanoparticle formulation of a potent Aurora Kinase B inhibitor used to treat solid tumors and hematologic malignancies. It is applied in the treatment of conditions such as anaplastic large cell lymphoma, kidney cancer, lung cancer, and prostate cancer, and is utilized by end-users including hospitals, research institutes, diagnostic laboratories, and others.

The aurora kinase B market research report is one of a series of new reports that provides aurora kinase B market statistics, including aurora kinase B industry global market size, regional shares, competitors with a aurora kinase B market share, detailed aurora kinase B market segments, market trends and opportunities, and any further data you may need to thrive in the aurora kinase B industry. This aurora kinase B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aurora kinase B market consists of sales of aurora kinase B inhibitors, antibodies, diagnostic kits, assay kits, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.